EULAV Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.8M Sell
9,010
-500
-5% -$511K 0.35% 79
2026
Q1
$8.75M Hold
9,510
0.28% 91
2025
Q4
$10.2M Buy
9,510
+10
+0.1% +$9.56K 0.27% 98
2025
Q3
$7.25M Hold
9,500
0.17% 114
2025
Q2
$7.41M Buy
+9,500
New +$7.38M 0.17% 112
2014
Q2
Sell
-22,500
Closed -$1.32M 398
2014
Q1
$1.32M Hold
22,500
0.07% 298
2013
Q4
$1.15M Buy
22,500
+3,000
+15% +$150K 0.06% 317
2013
Q3
$981K Sell
19,500
-500
-3% -$26.2K 0.06% 331
2013
Q2
$982K Buy
+20,000
New +$1.09M 0.06% 335

Other funds holding LLY

EULAV Asset Management's LLY Position: Q2 2026 in Review

EULAV Asset Management reduced its Eli Lilly (LLY) stake by 5.3% in Q2 2026, selling an estimated $511K and leaving 9,010 shares worth $10.8M. The position accounts for 0.35% of the portfolio, ranked #79.

EULAV Asset Management first reported a position in LLY in Q2 2013 and has held it in 9 quarters since. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • EULAV Asset Management held 9,010 shares of Eli Lilly worth $10.8M as of Q2 2026.
  • EULAV Asset Management sold 500 Eli Lilly shares in Q2 2026, an estimated $511K.
  • Eli Lilly made up 0.35% of EULAV Asset Management's portfolio in Q2 2026, its #79 holding.
  • EULAV Asset Management first reported a position in Eli Lilly in Q2 2013 and has held it in 9 quarters since.
  • 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on EULAV Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.